cerca CERCA
Domenica 09 Maggio 2021
Aggiornato: 15:36
Temi caldi

Salute_E_Benessere Chimica_E_Farmacia Salute_E_Benessere Chimica_E_Farmacia Chimica_E_Farmacia

Bionical Emas launches Managed Access Program for JZP 458 - a recombinant Crisantaspase produced in Pseudomonas fluorescens

WILLINGTON, England, April 8, 2021 /PRNewswire/ -- Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals' medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic Lymphoma (LBL) following hypersensitivity to E. Coli-derived asparaginases. The Managed Access Program provides a mechanism through which unsolicited physician requests, to fulfi...

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction

CORK, Ireland, March 17, 2021 /PRNewswire/ -- Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in the United States and tested 2 different strengths of minocycline against vehicle in a 1:1:1 randomization. This is the first dry eye therapy targeting MGD pa...

Micreos initiates clinical trial to evaluate world's first endolysin-drug as a therapy for Atopic Dermatitis

THE HAGUE, Netherlands, Sept. 22, 2020 /PRNewswire/ -- Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans.

/DISREGARD RELEASE: Sino Medical Sciences Technology Inc. (SINOMED)/

We are advised by Sino Medical Sciences Technology Inc. (SINOMED) that journalists and other readers should disregard the news release, SINOMED® Completes Last Patient Follow-Up of the PIONEER-III Pivotal US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent, issued 06-Jul-2020 over PR Newswire. The release was inadvertently issued early. A new version will be provided later today.

SINOMED® Completes Last Patient Follow-Up of the PIONEER-III Pivotal US and Japanese Trial of the BuMA Supreme® Coronary Drug-Eluting Stent

TIANJIN, China, July 6, 2020 /PRNewswire/ -- SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug Administration and Japanese Pharmaceuticals and Medical Devices Agency for the device approval. 

ora in
Prima pagina
in Evidenza